I think it now makes sense why Acadia didn’t do a deal for ROW. 2591 will make trof redundant as it has more indications and higher potency. I think Acadia will either do a deal for the whole company or walk away. Perhaps that explains the weaknesses in the SP. MOO DYOR
Ann: Validation for NNZ-2591 neurodevelopmental disorder pipeline, page-72
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.03 |
Change
0.175(1.36%) |
Mkt cap ! $1.626B | |||
| Open | High | Low | Value | Volume |
| $13.15 | $13.37 | $12.92 | $5.882M | 448.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 922 | $13.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.03 | 741 | 8 |
View Market Depth
| Last trade - 15.16pm 18/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |